Esperion Therapeutics (United States)
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan. Derived from Wikipedia licensed CC-BY-SA.
Open Access statistics for Esperion Therapeutics (United States), United States, covering academic research published from 2000 to 2025. Read More.
Open Access Percentage
53%
Total
Publications
199
Total Open
Publications
106
Total
Citations
14K
Open Access
Percentage
53%
Total
Publications
199
Total Open
Publications
106
Total
Citations
14K
Breakdown
Publisher Open
18%
Both
30%
Other Platform Open
6%
Closed
46%
Percentage of Open Access over time
Publisher Open
Both
Other Platform Open
Closed
Volume of Open Access over time
Open
Closed
Publisher Open
OA Journal 35%
33
Hybrid 32%
30
No Guarantees 33%
31
Other Platform Open
Domain 72%
52
Institution 51%
37
Other Internet 15%
11
Preprint 4%
3
Public 0%
0
Other Platform Locations
Name | Platform Type | Publications |
|---|---|---|
PubMed Central | Domain | 56 |
doaj.org OAI-PMH Repository | Institution | 20 |
Unknown Repository | Other Internet | 10 |
The University of Western Australia | Institution | 4 |
Royal Netherlands Academy of Arts and Sciences | Institution | 4 |
Washington University in St. Louis | Institution | 3 |
Imperial College London | Institution | 3 |
University of Milan | Institution | 2 |
medRxiv | Preprint | 2 |
Le Centre pour la Communication Scientifique Directe - HAL - Diderot | Institution | 2 |